Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

22 trials with published results (33%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

10.4%

7 terminated out of 67 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

31%

21 trials in Phase 3/4

Results Transparency

45%

22 of 49 completed with results

Key Signals

22 with results88% success

Data Visualizations

Phase Distribution

56Total
Not Applicable (17)
P 1 (9)
P 2 (9)
P 3 (17)
P 4 (4)

Trial Status

Completed49
Terminated7
Unknown5
Recruiting3
Active Not Recruiting1
Suspended1

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 49 completed trials

Clinical Trials (67)

Showing 20 of 20 trials
NCT05931575Phase 2RecruitingPrimary

Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease

NCT03074812Not ApplicableSuspendedPrimary

Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation

NCT07106021Phase 1RecruitingPrimary

A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease

NCT02339064Phase 3Active Not RecruitingPrimary

Infusion of Apomorphine: Long-term Safety Study

NCT01221948Phase 2CompletedPrimary

Vercise Implantable Stimulator for Treating Parkinson's Disease

NCT05094011Phase 1Not Yet RecruitingPrimary

Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease

NCT05671341CompletedPrimary

Comparison of Balance, Activity-specific Balance Confidence and Quality of Life in Parkinson's Patients

NCT02610231Phase 3CompletedPrimary

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

NCT01968031Phase 3CompletedPrimary

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

NCT01815281Not ApplicableTerminatedPrimary

Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progressive Supranuclear Palsy.

NCT01668407Not ApplicableCompletedPrimary

Robot Walking Rehabilitation in Parkinson's Disease

NCT03665493Not ApplicableCompletedPrimary

Dopamine Effect on Inhibitory Control

NCT02565628Phase 1CompletedPrimary

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

NCT05687799CompletedPrimary

Fatigue, Sleep and Quality of Life in Parkinson's Patients

NCT05691114Phase 1RecruitingPrimary

Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson's Disease

NCT00400634Phase 2CompletedPrimary

Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease

NCT05575479Completed

PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables

NCT03065192Phase 1CompletedPrimary

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

NCT05107531CompletedPrimary

Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing

NCT04524182Not ApplicableCompletedPrimary

The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease

Scroll to load more

Research Network

Activity Timeline